
Give your in-center patients the hope for a more active, longer life
HDF is a breakthrough treatment combining diffusion and convection processes to elevate the standard of in-center care. Utilizing advanced technology to remove more molecules—including middle molecule uremic toxins—HDF has the potential to improve patients' quality of life.
HDF combines diffusion (hemodialysis - HD) with convection (hemofiltration - HF) to remove middle molecules more efficiently. The advanced process leads to better clearance of toxins, waste, and excess fluid, leaving patients with cleaner blood, and in many cases, feeling better—right after treatment and beyond. The increased removal of toxins also helps to reduce inflammation and cardiovascular complications, supporting better clinical outcomes.
How HDF supports improved clinical outcomes
HDF utilizes a high-flux dialyzer, a new machine, and online fluid replacement to individualize the delivery of care. This advanced process can remove more middle molecules, including uremic toxins, for lower incidents of hypotension, less inflammation, and better preservation of albumin.

— Dr. Siddharth Bhatt, MD
Nephrologist
- Engaging patients with the potential treatment benefits
- Supporting their understanding of the hemodiafiltration process
- Guiding patients through expectations as they transition from HD to HDF

— Eduardo, On HDF
Help your in-center patients get the full benefits of HDF
As with conventional HD, it's essential for patients to complete their full treatment as prescribed to feel their best. Most patients are able to achieve the necessary HDF convective clearance with a 4-hour treatment, 3 days per week. Potential reduction in dialysis complications and improvement in energy and overall feeling of well-being on HDF are expected to support adherence to treatment time.
Prepare to start patients on HDF
As HDF comes to your market, help your patients transition so they can feel their best. Our algorithm can support you with prescribing HDF during the transition from HD.
Questions? Contact your Market Development Representative or email us.
References:
1. CONVINCE study: Effect of Hemodiafiltration or Hemodialysis on Mortality in Kidney Failure. The New England Journal of Medicine. Blankestijn et al. June 16, 2023. Comparison of high-dose HDF with high-flux HD in European patients. 2. Maduell et al. JASN (2013) 24(3):487-97. 3. Panichi et al. Nephrol Dial Transplant (2008) 23: 2337-43. 4. Advancing and Personalizing Kidney Disease Care: 2024 Annual Medical Report. Strategy to Expand High-Volume Hemodiafiltration Worldwide. Stefano Stuard, MD, PhD and Michael S. Anger, MD, FACP, FASN.

On HDF